Expert opinion on investigational drugs最新文献_第7页

Interleukin antagonists for atopic dermatitis: a new era of therapy. 白细胞介素拮抗剂治疗特应性皮炎：治疗新时代。

IF 6.1 2区医学

Expert opinion on investigational drugs Pub Date : 2024-04-24 DOI: 10.1080/13543784.2024.2347294

Aikaterini Tsiogka, Eleni Paschou, Dimitra Koumaki, E. Vakirlis, S. Gregoriou

{"title":"Interleukin antagonists for atopic dermatitis: a new era of therapy.","authors":"Aikaterini Tsiogka, Eleni Paschou, Dimitra Koumaki, E. Vakirlis, S. Gregoriou","doi":"10.1080/13543784.2024.2347294","DOIUrl":"https://doi.org/10.1080/13543784.2024.2347294","url":null,"abstract":"INTRODUCTION\u0000Over the last decade, increasing understanding of the immunopathogenesis of atopic dermatitis (AD) enabled the recognition of multiple therapeutic targets and subsequently the development of novel, highly effective systemic treatments, including interleukin (IL)-antagonists. To date, the IL-4Ra-inhibitor dupilumab, and the IL-13 inhibitor tralokinumab, have gained regulatory approval in Europe for the treatment of moderate-to-severe AD, while more than 70 new therapeutics are currently in development.\u0000\u0000\u0000AREAS COVERED\u0000In this review, we address the role of ILs in the pathogenesis of AD and provide an overview of the novel and investigational IL-antagonists, as regards their efficacy and safety on moderate-to-severe AD.\u0000\u0000\u0000EXPERT OPINION\u0000Current data have established IL-4 and IL-13 inhibitors as effective and safe for the treatment of moderate-to-severe AD, as regards the rapid control of flares as well as the long-term remission of the disease. Data regarding the efficacy and safety of other IL-inhibitors, including those targeting IL-31, IL-22, IL-33, IL-36 and IL-18, are accumulating. There is still an unmet need for real-world-evidence studies and head-to-head studies for both currently available and future agents in AD treatment. Establishing predictive biomarkers of treatment response in a disorder of such considerable heterogenicity might help physicians pursue a patient-tailored therapeutic response.","PeriodicalId":12313,"journal":{"name":"Expert opinion on investigational drugs","volume":null,"pages":null},"PeriodicalIF":6.1,"publicationDate":"2024-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140661194","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

TARGETING DIARRHEA-PREDOMINANT IRRITABLE BOWEL SYNDROME: HOPES or HYPES? 针对胰高血糖素引起的易激惹性肠易激综合征：希望还是奢望？

IF 6.1 2区医学

Expert opinion on investigational drugs Pub Date : 2024-04-23 DOI: 10.1080/13543784.2024.2347296

Gabrio Bassotti

引用次数: 0

Investigational drugs for the Treatment of Acromegaly: new agents to transform therapy. 治疗肢端肥大症的研究药物：改变疗法的新药。

IF 6.1 2区医学

Expert opinion on investigational drugs Pub Date : 2024-04-23 DOI: 10.1080/13543784.2024.2343056

R. Pirchio, R. S. Auriemma, A. Vergura, R. Pivonello, A. Colao

{"title":"Investigational drugs for the Treatment of Acromegaly: new agents to transform therapy.","authors":"R. Pirchio, R. S. Auriemma, A. Vergura, R. Pivonello, A. Colao","doi":"10.1080/13543784.2024.2343056","DOIUrl":"https://doi.org/10.1080/13543784.2024.2343056","url":null,"abstract":"INTRODUCTION\u0000Disease control is essential to decrease morbidity burden and mortality in acromegaly patients. In the last decades, the availability of new drugs increased the rate of disease control. However, up to 55% of patients remain uncontrolled despite available treatment strategies in real-world data. The reasons for this finding may include poor adherence, inadequate tolerability, therapeutic inertia, and high costs. Since acromegaly is a chronic disease and medical therapy is usually life-long, patient's adherence to treatment is fundamental in both achieving and maintaining disease control. Less invasive routes of administration could improve adherence and concur to increase disease control rate.\u0000\u0000\u0000AREAS COVERED\u0000The aim of current review is to provide a detailed update about investigational drugs for acromegaly treatment currently under investigation as paltusotine, ONO-5788, AP102, GT-02037, ISIS 766,720, CAM2024, Lanreotide PRF, DP1038, MTD201, solid dose injection of octreotide.\u0000\u0000\u0000EXPERT OPINION\u0000Medical therapy of acromegaly is an evolving field. Current studies are addressing patient's needing for both new molecules and less invasive routes of administration for already existing drugs. It cannot be ruled out that drugs currently used for other disease such as cancers could be considered in the future for the treatment of acromegaly.","PeriodicalId":12313,"journal":{"name":"Expert opinion on investigational drugs","volume":null,"pages":null},"PeriodicalIF":6.1,"publicationDate":"2024-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140668463","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Experimental and new investigational drugs for the treatment of uterine fibroids 治疗子宫肌瘤的试验性药物和新研究药物

IF 6.1 2区医学

Expert opinion on investigational drugs Pub Date : 2024-04-15 DOI: 10.1080/13543784.2024.2343786

Giulio Evangelisti, Simone Ferrero, Umberto Perrone, Claudio Gustavino, Eugenio Volpi, Alberto Izzotti, Fabio Barra

引用次数: 0

Investigational agents for autosomal dominant polycystic kidney disease: preclinical and early phase study insights 常染色体显性多囊肾病的研究药物：临床前和早期阶段研究的启示

IF 6.1 2区医学

Expert opinion on investigational drugs Pub Date : 2024-04-15 DOI: 10.1080/13543784.2024.2342327

Irene Capelli, Sarah Lerario, Francesca Ciurli, Gian Marco Berti, Valeria Aiello, Michele Provenzano, Gaetano Manna

引用次数: 0

Sodium/Bile acid co-transporter inhibitors currently in preclinical or early clinical development for the treatment of primary biliary cholangitis 目前正处于临床前或早期临床开发阶段的钠/胆酸协同转运体抑制剂，用于治疗原发性胆汁性胆管炎

IF 6.1 2区医学

Expert opinion on investigational drugs Pub Date : 2024-04-13 DOI: 10.1080/13543784.2024.2343789

Abhishek Gairola, Aaron Wetten, Jessica Dyson

引用次数: 0

Investigational regenerative medicine for non-traumatic osteonecrosis of the femoral head: a survey of registered clinical trials. 治疗非创伤性股骨头坏死的再生医学研究：注册临床试验调查。

IF 6.1 2区医学

Expert opinion on investigational drugs Pub Date : 2024-04-01 Epub Date: 2024-03-05 DOI: 10.1080/13543784.2024.2326622

Yutaka Kuroda, Toshiyuki Kawai, Yaichiro Okuzu, Yugo Morita, Shuichi Matsuda

{"title":"Investigational regenerative medicine for non-traumatic osteonecrosis of the femoral head: a survey of registered clinical trials.","authors":"Yutaka Kuroda, Toshiyuki Kawai, Yaichiro Okuzu, Yugo Morita, Shuichi Matsuda","doi":"10.1080/13543784.2024.2326622","DOIUrl":"10.1080/13543784.2024.2326622","url":null,"abstract":"Introduction: Osteonecrosis of the femoral head (ONFH) is a refractory disease requiring joint replacement in young patients. Regenerative therapies have been developed.Areas covered: This study surveyed clinical trials on regenerative medicine for ONFH. We extracted clinical trials on non-traumatic ONFH from the websites of five publicly available major registries (EuropeanUnion Clinical Trials Register ([EU-CTR],ClinicalTrials.gov, Chinese ClinicalTrial Registry [ChiCTR], University Hospital Medical InformationNetwork - Clinical Trial Registry [UMIN-CTR] and Australian New Zealand Clinical Trials Registry [ANZCTR]).The trials were classified into six categories based on purpose: surgical treatment, non-drug conservative treatment, conservative drug treatment, therapeutic strategy, diagnosis and pathogenesis, and regenerative therapy.) We extracted 169 clinical trials on ONFH. Of these, 37 were on regenerative medicine, including 29 on cell therapy. Surgical treatment was the most common treatment, followed by regenerative therapy.There were 9 clinical trials registered in the EU-CTR, with 5 on regenerative medicine; 79 trials registered on ClinicalTrials.gov, with 24 on regenerativemedicine; 54 trials registered in the ChiCTR, with 6 on regenerative medicine.Expert opinion: The focus of the joint-preserving surgery has shifted to regenerative therapy based on using cell therapy in early-stage ONFH. The global standardisation of regenerative therapy is still ongoing.","PeriodicalId":12313,"journal":{"name":"Expert opinion on investigational drugs","volume":null,"pages":null},"PeriodicalIF":6.1,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140021305","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Investigational drugs for the treatment of dysmenorrhea. 治疗痛经的研究药物。

IF 6.1 2区医学

Expert opinion on investigational drugs Pub Date : 2024-04-01 Epub Date: 2024-03-19 DOI: 10.1080/13543784.2024.2326627

Amelia K Mardon, Lucy Whitaker, Toobah Farooqi, Jane Girling, Claire Henry, Carolyn Ee, Jordan Tewhaiti-Smith, Mike Armour

{"title":"Investigational drugs for the treatment of dysmenorrhea.","authors":"Amelia K Mardon, Lucy Whitaker, Toobah Farooqi, Jane Girling, Claire Henry, Carolyn Ee, Jordan Tewhaiti-Smith, Mike Armour","doi":"10.1080/13543784.2024.2326627","DOIUrl":"10.1080/13543784.2024.2326627","url":null,"abstract":"Introduction: Dysmenorrhea is the most common cause of gynecological pain among women that has considerable impact on quality of life and psychosocial wellbeing. Non-steroidal anti-inflammatory drugs (NSAIDs) and hormonal therapies are most commonly used to treat dysmenorrhea. However, given these drugs are often associated with bothersome side effects and are less effective when there is an underlying cause contributing to dysmenorrhea (e.g. endometriosis), a patient-centered approach to managing dysmenorrhea is important. Various new drugs are currently being investigated for the treatment of primary and secondary dysmenorrhea.Areas covered: This review provides an updated overview on new therapeutic targets and investigational drugs for the treatment of primary and secondary dysmenorrhea. The authors describe the clinical development and implications of these drugs.Expert opinion: Among the investigative drugs discussed in this review, anti-inflammatories show the most promising results for the treatment of dysmenorrhea. However, given some trials have considerable methodological limitations, many drugs cannot be currently recommended. Research focused on understanding the mechanisms involved in menstruation and its associated symptoms will be important to identify new therapeutic targets for dysmenorrhea. Further robust clinical trials are required to better understand the efficacy and safety of investigational drugs for treating primary and secondary dysmenorrhea.","PeriodicalId":12313,"journal":{"name":"Expert opinion on investigational drugs","volume":null,"pages":null},"PeriodicalIF":6.1,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140021304","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Novel preclinical developments of the primary sclerosing cholangitis treatment landscape. 原发性硬化性胆管炎治疗的临床前新进展。

IF 6.1 2区医学

Expert opinion on investigational drugs Pub Date : 2024-04-01 Epub Date: 2024-03-18 DOI: 10.1080/13543784.2024.2330738

Aalam Sohal, Kris V Kowdley

引用次数: 0

Investigational new drugs for the treatment of chronic renal failure: an overview of the literature. 治疗慢性肾功能衰竭的试验性新药：文献综述。

IF 6.1 2区医学

Expert opinion on investigational drugs Pub Date : 2024-04-01 Epub Date: 2024-03-28 DOI: 10.1080/13543784.2024.2326624

Chiara Terzo, Guido Gembillo, Valeria Cernaro, Elisa Longhitano, Vincenzo Calabrese, Chiara Casuscelli, Luigi Peritore, Domenico Santoro

{"title":"Investigational new drugs for the treatment of chronic renal failure: an overview of the literature.","authors":"Chiara Terzo, Guido Gembillo, Valeria Cernaro, Elisa Longhitano, Vincenzo Calabrese, Chiara Casuscelli, Luigi Peritore, Domenico Santoro","doi":"10.1080/13543784.2024.2326624","DOIUrl":"10.1080/13543784.2024.2326624","url":null,"abstract":"Introduction: Chronic kidney disease (CKD) is widespread throughout the world, with a high social and health impact. It is considered a 'silent killer' for its sudden onset without symptoms in the early stages of the disease. The main goal of nephrologists is to slow the progression of kidney disease and treat the associated symptoms with a range of new medications.Areas covered: The aim of this systematic review is to analyze the new investigational drugs for the treatment of chronic renal failure. Data were obtained from the available scientific literature and from the ClinicalTrials.gov website.Expert opinion: Among the drugs currently being researched, SGLT2 inhibitors appear to be the most promising drugs for the treatment of CKD, has they have slower progression of CKD and protection of cardiorenal function. An important role in the future of CKD treatment is played by autologous cell-therapy, which appears to be a new frontier in the treatment of CKD. Other therapeutic strategies are currently being investigated and have been shown to slow the progression of CKD. However, further studies are needed to determine whether these approaches may offer benefits in slowing the progression of CKD in the near future.","PeriodicalId":12313,"journal":{"name":"Expert opinion on investigational drugs","volume":null,"pages":null},"PeriodicalIF":6.1,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140012533","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0